Ronald Potkul is an Oncology physician affiliated with Loyola University Medical Center. OpenAlex indexes 99 publications with 2,367 citations (h-index 25); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2160 S First Ave
Cardinal Bernadin Cancer Center
Maywood, IL 60153
Telephone
708-216-8563Provider last certified this registry record 11 Nov 2021.
Clinical trials
- S9630, Medroxyprogesterone in Treating Women With Breast Cancer
Sponsor: SWOG Cancer Research Network
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Intuitive Surgical, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
33.6%Estrogen20.2%Estradiol100%Part D≥24 patientsProgestin13.4%Megestrol Acetate100%Part D<11 patientsNervous system
27.7%Gabapentinoids7.6%Gabapentin100%Part D<11 patientsBenzodiazepine7.6%Lorazepam100%Part D≥13 patients+ 2 more classes in this area
Cancer & immunology
20.6%Aromatase Inhibitor10.9%Anastrozole100%Part D<11 patientsEstrogen Agonist/Antagonist9.7%Tamoxifen Citrate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Repurposing Kir6/SUR2 Channel Activator Minoxidil to Arrests Growth of Gynecologic Cancers
Frontiers in Pharmacology
2020 - Salvage treatment in recurrent endometrial cancer of the pelvis and peritoneal cavity
Gynecologic Oncology Reports
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Patrick Stiff, MD
Loyola University Medical Center
Pauline Camacho, MD
Loyola University Medical Center
Scott Cotler, MD
Loyola University Medical Center
Karen Griffin, MD
Loyola University Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”